Tags

Type your tag names separated by a space and hit enter

Telomerase activity as a prognostic indicator in stage I non-small cell lung cancer.
Clin Cancer Res. 1999 Aug; 5(8):2077-81.CC

Abstract

Patients with stage I non-small cell lung cancer (NSCLC) are typically treated with surgical resection alone. However, about one-third of such patients develop disease recurrence and die within 5 years after complete resection. The ability to predict recurrence could represent an important contribution to treatment planning. This study evaluates the presence of telomerase activity in tumor cells as a predictor of disease recurrence and cancer-related death after operation for stage I NSCLC patients. The activity of the telomerase enzyme was investigated by telomeric repeat amplification protocol (TRAP) in tumors and matching normal lung tissue samples obtained from 107 consecutive operable patients with pathological stage I NSCLC. Telomerase activity was detected in 66 (62%) of the 107 tumors examined and in none of the corresponding adjacent noncancerous lung tissue samples. Correlation with pathological parameters showed that telomerase activity was associated with histopathological grade (P = 0.0135) but not with tumor size or histological type. Univariate survival curves, estimated using the method of Kaplan and Meier, defined a significant association between telomerase activity and both disease-free survival (P = 0.0115) and overall survival (P = 0.0129). In multivariate analyses, performed by Cox's proportional hazards regression models, the presence of telomerase activity was the only strong predictor of disease-free survival (P = 0.0173) and overall survival (P = 0.0187). Our data indicate that telomerase activity can be an important prognostic factor that should be considered in future prospective trials of adjuvant therapy for high-risk stage I NSCLC patients.

Authors+Show Affiliations

Department of Oncology and Neurosciences, University Gabriele D'Annunzio, Chieti, Italy. amarchetti@unich.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10473089

Citation

Marchetti, A, et al. "Telomerase Activity as a Prognostic Indicator in Stage I Non-small Cell Lung Cancer." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, vol. 5, no. 8, 1999, pp. 2077-81.
Marchetti A, Bertacca G, Buttitta F, et al. Telomerase activity as a prognostic indicator in stage I non-small cell lung cancer. Clin Cancer Res. 1999;5(8):2077-81.
Marchetti, A., Bertacca, G., Buttitta, F., Chella, A., Quattrocolo, G., Angeletti, C. A., & Bevilacqua, G. (1999). Telomerase activity as a prognostic indicator in stage I non-small cell lung cancer. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 5(8), 2077-81.
Marchetti A, et al. Telomerase Activity as a Prognostic Indicator in Stage I Non-small Cell Lung Cancer. Clin Cancer Res. 1999;5(8):2077-81. PubMed PMID: 10473089.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Telomerase activity as a prognostic indicator in stage I non-small cell lung cancer. AU - Marchetti,A, AU - Bertacca,G, AU - Buttitta,F, AU - Chella,A, AU - Quattrocolo,G, AU - Angeletti,C A, AU - Bevilacqua,G, PY - 1999/9/3/pubmed PY - 1999/9/3/medline PY - 1999/9/3/entrez SP - 2077 EP - 81 JF - Clinical cancer research : an official journal of the American Association for Cancer Research JO - Clin Cancer Res VL - 5 IS - 8 N2 - Patients with stage I non-small cell lung cancer (NSCLC) are typically treated with surgical resection alone. However, about one-third of such patients develop disease recurrence and die within 5 years after complete resection. The ability to predict recurrence could represent an important contribution to treatment planning. This study evaluates the presence of telomerase activity in tumor cells as a predictor of disease recurrence and cancer-related death after operation for stage I NSCLC patients. The activity of the telomerase enzyme was investigated by telomeric repeat amplification protocol (TRAP) in tumors and matching normal lung tissue samples obtained from 107 consecutive operable patients with pathological stage I NSCLC. Telomerase activity was detected in 66 (62%) of the 107 tumors examined and in none of the corresponding adjacent noncancerous lung tissue samples. Correlation with pathological parameters showed that telomerase activity was associated with histopathological grade (P = 0.0135) but not with tumor size or histological type. Univariate survival curves, estimated using the method of Kaplan and Meier, defined a significant association between telomerase activity and both disease-free survival (P = 0.0115) and overall survival (P = 0.0129). In multivariate analyses, performed by Cox's proportional hazards regression models, the presence of telomerase activity was the only strong predictor of disease-free survival (P = 0.0173) and overall survival (P = 0.0187). Our data indicate that telomerase activity can be an important prognostic factor that should be considered in future prospective trials of adjuvant therapy for high-risk stage I NSCLC patients. SN - 1078-0432 UR - https://www.unboundmedicine.com/medline/citation/10473089/Telomerase_activity_as_a_prognostic_indicator_in_stage_I_non_small_cell_lung_cancer_ DB - PRIME DP - Unbound Medicine ER -